 | • レポートコード：MRC2-11QY11557 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、130ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はサイトメガロウイルス（HHV-5）感染症治療薬のグローバル市場について調査・分析したレポートです。種類別（経口薬、注射）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別サイトメガロウイルス（HHV-5）感染症治療薬の競争状況、市場シェア ・世界のサイトメガロウイルス（HHV-5）感染症治療薬市場：種類別市場規模 2015年-2020年（経口薬、注射） ・世界のサイトメガロウイルス（HHV-5）感染症治療薬市場：種類別市場規模予測 2021年-2026年（経口薬、注射） ・世界のサイトメガロウイルス（HHV-5）感染症治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック、その他） ・世界のサイトメガロウイルス（HHV-5）感染症治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック、その他） ・北米のサイトメガロウイルス（HHV-5）感染症治療薬市場分析：米国、カナダ ・ヨーロッパのサイトメガロウイルス（HHV-5）感染症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのサイトメガロウイルス（HHV-5）感染症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のサイトメガロウイルス（HHV-5）感染症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのサイトメガロウイルス（HHV-5）感染症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：3-V Biosciences, Inc.、AIMM Therapeutics、AlphaVax、Altor BioScience、Applied Immune、Astellas、BioApex、Bionor Pharma、Biotest、Pfizer、Cell Medica、Chimerix、GSK、Hookipa Biotech、Humabs BioMed、Inagen、Kadmon Corporation、Lead Discovery Center、Merck、Novartis ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
A drug used to treat giant cell infections.
Market Analysis and Insights: Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market
The global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs market.
Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Scope and Market Size
Cytomegalovirus（HHV-5）Infection Therapeutic Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Oral Medication
Injection
Market segment by Application, split into
Hospital
Clinic
Other
Based on regional and country-level analysis, the Cytomegalovirus（HHV-5）Infection Therapeutic Drugs market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
3-V Biosciences, Inc.
AIMM Therapeutics
AlphaVax
Altor BioScience
Applied Immune
Astellas
BioApex
Bionor Pharma
Biotest
Pfizer
Cell Medica
Chimerix
GSK
Hookipa Biotech
Humabs BioMed
Inagen
Kadmon Corporation
Lead Discovery Center
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Oral Medication
1.2.3 Injection
1.3 Market by Application
1.3.1 Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Perspective (2015-2026)
2.2 Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Growth Trends by Regions
2.2.1 Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Players by Market Size
3.1.1 Global Top Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Players by Revenue (2015-2020)
3.1.2 Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Revenue Market Share by Players (2015-2020)
3.2 Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Revenue
3.4 Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Concentration Ratio
3.4.1 Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Revenue in 2019
3.5 Key Players Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Area Served
3.6 Key Players Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Product Solution and Service
3.7 Date of Enter into Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Breakdown Data by Type (2015-2026)
4.1 Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Historic Market Size by Type (2015-2020)
4.2 Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Forecasted Market Size by Type (2021-2026)
5 Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Breakdown Data by Application (2015-2026)
5.1 Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Historic Market Size by Application (2015-2020)
5.2 Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size (2015-2026)
6.2 North America Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Type (2015-2020)
6.3 North America Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Application (2015-2020)
6.4 North America Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size (2015-2026)
7.2 Europe Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Type (2015-2020)
7.3 Europe Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Application (2015-2020)
7.4 Europe Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size (2015-2026)
8.2 China Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Type (2015-2020)
8.3 China Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Application (2015-2020)
8.4 China Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size (2015-2026)
9.2 Japan Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Type (2015-2020)
9.3 Japan Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Application (2015-2020)
9.4 Japan Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size (2015-2026)
10.2 Southeast Asia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Type (2015-2020)
10.3 Southeast Asia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Application (2015-2020)
10.4 Southeast Asia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11Key Players Profiles
11.1 3-V Biosciences, Inc.
11.1.1 3-V Biosciences, Inc. Company Details
11.1.2 3-V Biosciences, Inc. Business Overview
11.1.3 3-V Biosciences, Inc. Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
11.1.4 3-V Biosciences, Inc. Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020))
11.1.5 3-V Biosciences, Inc. Recent Development
11.2 AIMM Therapeutics
11.2.1 AIMM Therapeutics Company Details
11.2.2 AIMM Therapeutics Business Overview
11.2.3 AIMM Therapeutics Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
11.2.4 AIMM Therapeutics Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
11.2.5 AIMM Therapeutics Recent Development
11.3 AlphaVax
11.3.1 AlphaVax Company Details
11.3.2 AlphaVax Business Overview
11.3.3 AlphaVax Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
11.3.4 AlphaVax Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
11.3.5 AlphaVax Recent Development
11.4 Altor BioScience
11.4.1 Altor BioScience Company Details
11.4.2 Altor BioScience Business Overview
11.4.3 Altor BioScience Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
11.4.4 Altor BioScience Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
11.4.5 Altor BioScience Recent Development
11.5 Applied Immune
11.5.1 Applied Immune Company Details
11.5.2 Applied Immune Business Overview
11.5.3 Applied Immune Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
11.5.4 Applied Immune Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
11.5.5 Applied Immune Recent Development
11.6 Astellas
11.6.1 Astellas Company Details
11.6.2 Astellas Business Overview
11.6.3 Astellas Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
11.6.4 Astellas Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
11.6.5 Astellas Recent Development
11.7 BioApex
11.7.1 BioApex Company Details
11.7.2 BioApex Business Overview
11.7.3 BioApex Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
11.7.4 BioApex Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
11.7.5 BioApex Recent Development
11.8 Bionor Pharma
11.8.1 Bionor Pharma Company Details
11.8.2 Bionor Pharma Business Overview
11.8.3 Bionor Pharma Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
11.8.4 Bionor Pharma Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
11.8.5 Bionor Pharma Recent Development
11.9 Biotest
11.9.1 Biotest Company Details
11.9.2 Biotest Business Overview
11.9.3 Biotest Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
11.9.4 Biotest Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
11.9.5 Biotest Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Details
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
11.10.4 Pfizer Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
11.10.5 Pfizer Recent Development
11.11 Cell Medica
10.11.1 Cell Medica Company Details
10.11.2 Cell Medica Business Overview
10.11.3 Cell Medica Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
10.11.4 Cell Medica Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
10.11.5 Cell Medica Recent Development
11.12 Chimerix
10.12.1 Chimerix Company Details
10.12.2 Chimerix Business Overview
10.12.3 Chimerix Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
10.12.4 Chimerix Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
10.12.5 Chimerix Recent Development
11.13 GSK
10.13.1 GSK Company Details
10.13.2 GSK Business Overview
10.13.3 GSK Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
10.13.4 GSK Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
10.13.5 GSK Recent Development
11.14 Hookipa Biotech
10.14.1 Hookipa Biotech Company Details
10.14.2 Hookipa Biotech Business Overview
10.14.3 Hookipa Biotech Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
10.14.4 Hookipa Biotech Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
10.14.5 Hookipa Biotech Recent Development
11.15 Humabs BioMed
10.15.1 Humabs BioMed Company Details
10.15.2 Humabs BioMed Business Overview
10.15.3 Humabs BioMed Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
10.15.4 Humabs BioMed Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
10.15.5 Humabs BioMed Recent Development
11.16 Inagen
10.16.1 Inagen Company Details
10.16.2 Inagen Business Overview
10.16.3 Inagen Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
10.16.4 Inagen Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
10.16.5 Inagen Recent Development
11.17 Kadmon Corporation
10.17.1 Kadmon Corporation Company Details
10.17.2 Kadmon Corporation Business Overview
10.17.3 Kadmon Corporation Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
10.17.4 Kadmon Corporation Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
10.17.5 Kadmon Corporation Recent Development
11.18 Lead Discovery Center
10.18.1 Lead Discovery Center Company Details
10.18.2 Lead Discovery Center Business Overview
10.18.3 Lead Discovery Center Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
10.18.4 Lead Discovery Center Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
10.18.5 Lead Discovery Center Recent Development
11.19 Merck
10.19.1 Merck Company Details
10.19.2 Merck Business Overview
10.19.3 Merck Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
10.19.4 Merck Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
10.19.5 Merck Recent Development
11.20 Novartis
10.20.1 Novartis Company Details
10.20.2 Novartis Business Overview
10.20.3 Novartis Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Introduction
10.20.4 Novartis Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
10.20.5 Novartis Recent Development
12Analyst’s Viewpoints/Conclusions
13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Oral Medication
Table 4. Key Players of Injection
Table 5. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 6. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 7. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 8. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Regions (2015-2020)
Table 9. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 10. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Regions (2021-2026)
Table 11. Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Market Trends
Table 12. Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Drivers
Table 13. Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Challenges
Table 14. Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Restraints
Table 15. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Revenue by Players (2015-2020) (US$ Million)
Table 16. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Players (2015-2020)
Table 17. Global Top Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs as of 2019)
Table 18. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Product Solution and Service
Table 21. Mergers & Acquisitions, Expansion Plans
Table 22. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Type (2015-2020) (US$ Million)
Table 23. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size Share by Type (2015-2020)
Table 24. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Revenue Market Share by Type (2021-2026)
Table 25. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size Share by Application (2015-2020)
Table 26. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Application (2015-2020) (US$ Million)
Table 27. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size Share by Application (2021-2026)
Table 28. North America Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Type (2015-2020) (US$ Million)
Table 29. North America Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Type (2015-2020)
Table 30. North America Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Application (2015-2020) (US$ Million)
Table 31. North America Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Application (2015-2020)
Table 32. North America Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Country (US$ Million) (2015-2020)
Table 33. North America Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Country (2015-2020)
Table 34. Europe Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Type (2015-2020) (US$ Million)
Table 35. Europe Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Type (2015-2020)
Table 36. Europe Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Application (2015-2020) (US$ Million)
Table 37. Europe Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Application (2015-2020)
Table 38. Europe Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Country (US$ Million) (2015-2020)
Table 39. Europe Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Country (2015-2020)
Table 40. China Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Type (2015-2020) (US$ Million)
Table 41. China Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Type (2015-2020)
Table 42. China Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Application (2015-2020) (US$ Million)
Table 43. China Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Application (2015-2020)
Table 44. China Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Region (US$ Million) (2015-2020)
Table 45. China Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Region (2015-2020)
Table 46. Japan Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Type (2015-2020) (US$ Million)
Table 47. Japan Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Type (2015-2020)
Table 48. Japan Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Application (2015-2020) (US$ Million)
Table 49. Japan Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Application (2015-2020)
Table 50. Japan Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Country (US$ Million) (2015-2020)
Table 51. Japan Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Country (2015-2020)
Table 52. Southeast Asia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Type (2015-2020) (US$ Million)
Table 53. Southeast Asia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Type (2015-2020)
Table 54. Southeast Asia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Application (2015-2020) (US$ Million)
Table 55. Southeast Asia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Application (2015-2020)
Table 56. Southeast Asia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size by Country (US$ Million) (2015-2020)
Table 57. Southeast Asia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Country (2015-2020)
Table 58. 3-V Biosciences, Inc. Company Details
Table 59. 3-V Biosciences, Inc. Business Overview
Table 60. 3-V Biosciences, Inc. Product
Table 61. 3-V Biosciences, Inc. Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 62. 3-V Biosciences, Inc. Recent Development
Table 63. AIMM Therapeutics Company Details
Table 64. AIMM Therapeutics Business Overview
Table 65. AIMM Therapeutics Product
Table 66. AIMM Therapeutics Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 67. AIMM Therapeutics Recent Development
Table 68. AlphaVax Company Details
Table 69. AlphaVax Business Overview
Table 70. AlphaVax Product
Table 71. AlphaVax Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 72. AlphaVax Recent Development
Table 73. Altor BioScience Company Details
Table 74. Altor BioScience Business Overview
Table 75. Altor BioScience Product
Table 76. Altor BioScience Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 77. Altor BioScience Recent Development
Table 78. Applied Immune Company Details
Table 79. Applied Immune Business Overview
Table 80. Applied Immune Product
Table 81. Applied Immune Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 82. Applied Immune Recent Development
Table 83. Astellas Company Details
Table 84. Astellas Business Overview
Table 85. Astellas Product
Table 86. Astellas Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 87. Astellas Recent Development
Table 88. BioApex Company Details
Table 89. BioApex Business Overview
Table 90. BioApex Product
Table 91. BioApex Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 92. BioApex Recent Development
Table 93. Bionor Pharma Business Overview
Table 94. Bionor Pharma Product
Table 95. Bionor Pharma Company Details
Table 96. Bionor Pharma Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 97. Bionor Pharma Recent Development
Table 98. Biotest Company Details
Table 99. Biotest Business Overview
Table 100. Biotest Product
Table 101. Biotest Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 102. Biotest Recent Development
Table 103. Pfizer Company Details
Table 104. Pfizer Business Overview
Table 105. Pfizer Product
Table 106. Pfizer Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 107. Pfizer Recent Development
Table 108. Cell Medica Company Details
Table 109. Cell Medica Business Overview
Table 110. Cell Medica Product
Table 111. Cell Medica Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 112. Cell Medica Recent Development
Table 113. Chimerix Company Details
Table 114. Chimerix Business Overview
Table 115. Chimerix Product
Table 116. Chimerix Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 117. Chimerix Recent Development
Table 118. GSK Company Details
Table 119. GSK Business Overview
Table 120. GSK Product
Table 121. GSK Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 122. GSK Recent Development
Table 123. Hookipa Biotech Company Details
Table 124. Hookipa Biotech Business Overview
Table 125. Hookipa Biotech Product
Table 126. Hookipa Biotech Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 127. Hookipa Biotech Recent Development
Table 128. Humabs BioMed Company Details
Table 129. Humabs BioMed Business Overview
Table 130. Humabs BioMed Product
Table 131. Humabs BioMed Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 132. Humabs BioMed Recent Development
Table 133. Inagen Company Details
Table 134. Inagen Business Overview
Table 135. Inagen Product
Table 136. Inagen Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 137. Inagen Recent Development
Table 138. Kadmon Corporation Company Details
Table 139. Kadmon Corporation Business Overview
Table 140. Kadmon Corporation Product
Table 141. Kadmon Corporation Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 142. Kadmon Corporation Recent Development
Table 143. Lead Discovery Center Company Details
Table 144. Lead Discovery Center Business Overview
Table 145. Lead Discovery Center Product
Table 146. Lead Discovery Center Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 147. Lead Discovery Center Recent Development
Table 148. Merck Company Details
Table 149. Merck Business Overview
Table 150. Merck Product
Table 151. Merck Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 152. Merck Recent Development
Table 153. Novartis Company Details
Table 154. Novartis Business Overview
Table 155. Novartis Product
Table 156. Novartis Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020) (US$ Million)
Table 157. Novartis Recent Development
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Type: 2020 VS 2026
Figure 2. Oral Medication Features
Figure 3. Injection Features
Figure 4. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Application: 2020 VS 2026
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Other Case Studies
Figure 8. Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Report Years Considered
Figure 9. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size (US$ Million), YoY Growth 2015-2026
Figure 10. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Regions: 2020 VS 2026
Figure 11. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Regions (2021-2026)
Figure 12. Global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Share by Players in 2019
Figure 13. Global Top Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs as of 2019
Figure 14. The Top 10 and 5 Players Market Share by Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Revenue in 2019
Figure 15. North America Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 16. United States Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 17. Canada Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 18. Europe Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. Germany Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. France Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. U.K. Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. Italy Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. Russia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. Nordic Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Rest of Europe Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Asia-Pacific Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. China Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Japan Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. South Korea Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Southeast Asia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. India Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. Australia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. Rest of Asia-Pacific Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Latin America Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Mexico Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Brazil Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Middle East & Africa Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Turkey Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Saudi Arabia Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. UAE Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Rest of Middle East & Africa Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. 3-V Biosciences, Inc. Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 43. AIMM Therapeutics Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 44. AlphaVax Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 45. Altor BioScience Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 46. Applied Immune Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 47. Astellas Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 48. BioApex Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 49. Bionor Pharma Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 50. Biotest Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 51. Pfizer Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 52. Cell Medica Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 53. Chimerix Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 54. GSK Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 55. Hookipa Biotech Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 56. Humabs BioMed Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 57. Inagen Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 58. Kadmon Corporation Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 59. Lead Discovery Center Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 60. Merck Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 61. Novartis Revenue Growth Rate in Cytomegalovirus（HHV-5）Infection Therapeutic Drugs Business (2015-2020)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
サイトメガロウイルス（CMV）感染症の世界市場（～2026年） Cytomegalovirus (CMV) infection is one of the common herpesvirus infection with different symptoms, which occurs in people of all ages across the globe. This viral infection is communicable and can easily spread through body fluids such as blood, urine, saliva, semen and breast milk. The infection c…- サイトメガロウイルス（CMV）治療薬の世界市場（～2026年） Market Analysis and Insights: Global Cytomegalovirus Therapeutics Market The global Cytomegalovirus Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Cytomegalovirus Therapeutics Scope and Market Size Cytome…
- サイトメガロウイルス（CMV）網膜炎治療の世界市場（～2026年） Ophthalmology is the branch of medical science that deals with the management and study of anatomy, physiology, and diseases related to the human eye. Globally, the incidence of eye disorders and vision loss are becoming major public health issues. Some of the major eye diseases include age-related …
- 眼科用治療薬の世界市場（～2026年） Market Analysis and Insights: Global Ophthalmic Therapeutic Drugs Market The global Ophthalmic Therapeutic Drugs market size is projected to reach US$ 16740 million by 2026, from US$ 15860 million in 2020, at a CAGR of 5.2%% during 2021-2026. Global Ophthalmic Therapeutic Drugs Scope and Market Size…
- 院内感染治療の世界市場（～2026年） Hospital-acquired infections, also known as nosocomial infections, are acquired by patients in the hospitals or healthcare facilities. Urinary tract infections, bloodstream infections, surgical-site infections, Clostridium difficile associated diarrhea, and pneumonia are examples of nosocomial infec…